- Leading key opinion leaders to review the treatment landscape in breast and prostate cancer and the importance of targeting the PI3K/mTOR pathway in hormonally driven tumor types
- Discussion of the planned Phase 1b/2 trial for gedatolisib in combination with Nubeqa® (darolutamide) in patients with mCRPC
- Event to be webcast from 10:00 a.m. – 12:00 p.m. ET on September 21, 2023
MINNEAPOLIS, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will host a Virtual Science Day for analysts and investors from 10:00 a.m. – 12:00 p.m. ET on Thursday, September 21, 2023. During this informative event, Celcuity will provide an in-depth overview of its lead compound, the equipotent pan-PI3K/mTOR inhibitor gedatolisib, discuss the importance of comprehensive, rather than selective, inhibition of the PI3K/mTOR pathway, and review its anticipated clinical development strategy in breast and prostate cancer.
The Phase 3 (VIKTORIA-1) global registration trial with gedatolisib is currently enrolling patients with HR+/HER2- advanced breast cancer whose disease progressed while receiving a CDK4/6 inhibitor. In early 2024, Celcuity expects to initiate the Phase 1b/2 CELC-G-201 trial of gedatolisib in combination with the androgen receptor inhibitor Nubeqa® (darolutamide) in metastatic castration resistant prostate cancer.
"We look forward to providing additional insights about gedatolisib's highly differentiated mechanism of action and how, we believe, this MOA can enable gedatolisib to potentially obtain several blockbuster indications," said Brian Sullivan, Chief Executive Officer and co-founder of Celcuity.
Key opinion leaders speaking at Celcuity's Virtual Science Day will include two leading oncologists:
- Sara Hurvitz, M.D., Head of the Division of Hematology and Oncology at the University of Washington Department of Medicine, Senior Vice President, Clinical Research Division at Fred Hutchinson Cancer Center. Formerly, she was the Director of the Breast Cancer Clinical Trials Program at UCLA.
- Karim Fizazi, M.D., Ph.D., Professor of Oncology at the University of Paris-Saclay, and former head of the department of oncology medicine at Gustav Roussy specializing in the treatment of prostate cancer.
Registration Information
Celcuity's ...